ClinicalTrials.gg
CompletedNCT03597139Updated Jul 8, 2021Results posted

Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease

A Phase 2 interventional study of Voclosporin Ophthalmic Solution and Restasis® in Dry Eye, sponsored by Aurinia Pharmaceuticals Inc.. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-08.

Sponsored by Aurinia Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.

Enrollment
183rd of 473
100 · median 60
Started
2018
with 35 others
Phase 2
97 of 544
5 open now
Registered
266th of 544
by date

Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 183rd largest by enrollment of the 473 interventional ones that give a count, is one of 36 that started in 2018, is one of 97 in phase 2, and was the 266th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 544 studies in Dry Eye Syndromes with a site in United States, or all of them as a file.
02

Study summary

Evaluate the tolerability, efficacy and safety of VOS versus Restasis® in subjects with mild to moderate Dry Eye Disease (DED).

Read the detailed description

This is a Phase 2, multi-center, Investigator-masked, randomized, parallel-group study to evaluate the tolerability, efficacy and safety of VOS versus Restasis® over a 28-day treatment period in subjects with mild to moderate DED. Approximately 90 subjects will be randomized to either VOS or Restasis® at approximately 7 centers located in the US

03

Conditions studied

  • Dry Eye

Browse trials for

Keywords

  • Dry Eye
  • Calcineurin Inhibitors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have a best corrected visual acuity (BCVA) in both eyes of +0.7 logarithm of the Minimum Angle of Resolution (logMAR) or better as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) chart.
  2. Have a documented history of DED in both eyes supported by a previous clinical diagnosis.
  3. Have ongoing DED, as defined by at least one eye (if one eye, the same eye) meeting all the following criteria:

    • A symptom severity score of ≥30 for Eye Dryness on a Visual Analog Scale (VAS) (0-100)
    • An unanesthetized Schirmer Tear Test (STT) score of ≥1 mm and ≤10 mm per 5 minutes (Note: STT Score obtained at Visit 1)
    • Evidence of ocular surface staining (total fluorescein staining score of at least 3 [0-15 scale]).
  4. Have normal lid anatomy.

Exclusion criteria

Exclusion Criteria:

  1. Have any known or to study treatments (including ), topical anesthetics or vital dyes.
  2. Be unable to demonstrate correct instillation of over-the-counter (OTC) ocular lubricant.
  3. Report discomfort in both eyes from instillation of OTC ocular lubricant during Visit 2 (based on score of ≥30 on the Drop Discomfort VAS).
  4. Have used Restasis® (cyclosporine ophthalmic emulsion) within 30 days prior to Visit 1.
  5. Have used Restasis® for more than 1 month (if prior use is reported).
  6. Have used Xiidra® (lifitegrast ophthalmic solution) within 14 days prior to Visit 1.
  7. Have had corneal graft surgery in either eye within 1 year.
  8. Have recent or current evidence of ocular infection or inflammation in either eye.
  9. Have current evidence of blepharitis (defined as requiring lid hygiene therapy), conjunctivitis, or a history of herpes simplex or zoster keratitis in either eye.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Voclosporin ophthalmic solution (VOS)

    0.2% VOS, Twice Daily (BID), both eyes for 28 days

    Drug: Voclosporin Ophthalmic Solution

  • Active comparator
    Comparator

    0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days

    Drug: Restasis®

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Drop Discomfort Post Dose Instillation on Day 1

    Drop Discomfort was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment 1 minute post-instillation on Day 1. The VAS scale is 0 - 100, where 0 corresponds to "no discomfort" and 100 corresponds to "maximal discomfort".

    Time frame: 1-minute Post Dose 1 installation (Day 1)

Secondary outcomes

  1. Change From Baseline in Drop Discomfort Post Dose Instillation on Day 28

    Drop Discomfort was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment 1 minute post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no discomfort" and 100 corresponds to "maximal discomfort".

    Time frame: Day 28

  2. Change From Baseline in Burning/Stinging Post Dose Instillation on Day 28

    Burning/Stinging was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no burning/stinging" and 100 corresponds to "worst burning/stinging".

    Time frame: Day 28

  3. Change From Baseline in Foreign Body Sensation Post Dose Instillation on Day 28

    Foreign Body Sensation was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no foreign body sensation" and 100 corresponds to "worst foreign body sensation".

    Time frame: 28 days

  4. Change From Baseline in Photophobia Post Dose Instillation on Day 28

    Photophobia was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no photophobia" and 100 corresponds to "worst photophobia".

    Time frame: 28 days

  5. Change From Baseline in Eye Pain Post Dose Instillation on Day 28

    Eye pain was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no eye pain" and 100 corresponds to "worst eye pain".

    Time frame: 28 days

  6. Change From Baseline in Eye Dryness Post Dose Instillation on Day 28

    Eye dryness was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no eye dryness" and 100 corresponds to "worst eye dryness".

    Time frame: 28 days

  7. Change From Baseline in Itching Post Dose Instillation on Day 28

    Itching was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no itching" and 100 corresponds to "worst itching".

    Time frame: 28 days

  8. Change From Baseline in the Total of All Individual Symptom Severity Assessment Scores

    The Individual Symptom Severity Assessment Visual Analog Scale (VAS) includes Burning/Stinging (scale 0 - 100; 0 = no Burning/Stinging, 100 = worst Burning/Stinging), Foreign Body Sensation (scale 0 - 100; 0 = no Foreign Body Sensation, 100 = worst Foreign Body Sensation), Photophobia (scale 0 - 100; 0 = no Photophobia, 100 = worst Photophobia), Eye Pain (scale 0 - 100; 0 = no Eye Pain, 100 = worst Eye Pain), Eye Dryness (scale 0 - 100; 0 = no Eye Dryness, 100 = worst Eye Dryness), and Itching (scale 0 - 100; 0 = no Itching, 100 = worst Itching). The total sum of all 6 symptoms (Burning/Stinging, Foreign Body Sensation, Photophobia, Eye Pain, Eye Dryness, Itching) were evaluated (scale 0 - 600; 0 = no visual symptoms, 600 = worst visual symptoms).

    Time frame: Day 28

  9. Change From Baseline in Symptom Assessment in Dry Eye Score (SANDE)

    The Symptom Assessment in Dry Eye (SANDE) is a subjective rating performed by the subjects for the frequency and severity of their dry eye symptoms. The total length of the line is 100mm. For Frequency of Symptoms 0mm = "rarely" and 100mm = "all the time". For Severity of Symptoms 0mm = "very mild" and 100mm = "very severe". Subjects were asked to subjectively rate the frequency and severity of their symptoms by placing an "X" on the relevant horizontal line. The length of the line between the "rarely" or "very mild" starting point and the first point where the subject's mark crosses each line was measured and recorded in millimeters.

    Time frame: Day 28

  10. Change From Baseline in Unanesthetized Schirmer Test Score

    The Schirmer Test Score recorded tear production on test strips. The Schirmer tear test was conducted 1 hour following administration of VOS/Comparator and 20 minutes following fluorescein corneal staining. Using a ruler and/or the millimeters recorded on the strips, a point halfway between the two lines was measured and this was recorded as the amount of wetting. Lower scores indicate less tear production and therefore a worse outcome. Normal tear production is ≥10mm of wetting on the test strip, and severe dry eye is \<5mm of wetting on the test strip.

    Time frame: 28 days

  11. Change From Baseline in Fluorescein Corneal Staining (FCS) Score

    The FCS score was summarized for each eye separately. Each of the 5 sections of cornea (superior, inferior, nasal, temporal, central) were graded using the National Eye Institute (NEI) scale; 0, 1 (mild), 2 (moderate), or 3 (severe). The total score was obtained by summing each of the 5 sections of the cornea from 0 - 15. Lower scores indicate less staining and therefore a better outcome.

    Time frame: 28 days

07

Results

Posted Jul 8, 2021

Participant flow

Recruitment period from August 2018 - December 2018

Participant flow — Overall Study
MilestoneVoclosporin Ophthalmic Solution (VOS)Comparator
Started5149
Completed4749
Not completed40
Withdrew: Adverse event30
Withdrew: Protocol non-compliance10

Outcome measures

PrimaryChange From Baseline in Drop Discomfort Post Dose Instillation on Day 1

Drop Discomfort was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment 1 minute post-instillation on Day 1. The VAS scale is 0 - 100, where 0 corresponds to "no discomfort" and 100 corresponds to "maximal discomfort".

Time frame:
1-minute Post Dose 1 installation (Day 1)
Reported as:
Mean · mm
Change From Baseline in Drop Discomfort Post Dose Instillation on Day 1
mmVoclosporin Ophthalmic Solution (VOS)Comparator
Change From Baseline in Drop Discomfort Post Dose Instillation on Day 17.9 ± 17.953.5 ± 13.30
Statistical analysis
  • Voclosporin Ophthalmic Solution (VOS) vs Comparator · ANCOVA · p = 0.1491 · Mean difference (final values): 4.6 · 95% CI -1.7 to 10.9
SecondaryChange From Baseline in Drop Discomfort Post Dose Instillation on Day 28

Drop Discomfort was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment 1 minute post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no discomfort" and 100 corresponds to "maximal discomfort".

Time frame:
Day 28
Reported as:
Mean · mm
Change From Baseline in Drop Discomfort Post Dose Instillation on Day 28
mmVoclosporin Ophthalmic Solution (VOS)Comparator
Change From Baseline in Drop Discomfort Post Dose Instillation on Day 2811.8 ± 20.646.1 ± 17.79
Statistical analysis
  • Voclosporin Ophthalmic Solution (VOS) vs Comparator · ANCOVA · p = 0.1187 · Mean difference (final values): 6.1 · 95% CI -1.6 to 13.9
SecondaryChange From Baseline in Burning/Stinging Post Dose Instillation on Day 28

Burning/Stinging was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no burning/stinging" and 100 corresponds to "worst burning/stinging".

Time frame:
Day 28
Reported as:
Mean · mm
Change From Baseline in Burning/Stinging Post Dose Instillation on Day 28
mmVoclosporin Ophthalmic Solution (VOS)Comparator
Change From Baseline in Burning/Stinging Post Dose Instillation on Day 28-12.3 ± 33.22-20.1 ± 25.11
Statistical analysis
  • Voclosporin Ophthalmic Solution (VOS) vs Comparator · ANCOVA · p = 0.2128 · Mean difference (final values): 6.4 · 95% CI -3.7 to 16.5
SecondaryChange From Baseline in Foreign Body Sensation Post Dose Instillation on Day 28

Foreign Body Sensation was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no foreign body sensation" and 100 corresponds to "worst foreign body sensation".

Time frame:
28 days
Reported as:
Mean · mm
Change From Baseline in Foreign Body Sensation Post Dose Instillation on Day 28
mmVoclosporin Ophthalmic Solution (VOS)Comparator
Change From Baseline in Foreign Body Sensation Post Dose Instillation on Day 28-19.7 ± 35.8-20.7 ± 32.95
Statistical analysis
  • Voclosporin Ophthalmic Solution (VOS) vs Comparator · ANCOVA · p = 0.8408 · Mean difference (final values): -1.1 · 95% CI -11.8 to 9.6
SecondaryChange From Baseline in Photophobia Post Dose Instillation on Day 28

Photophobia was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no photophobia" and 100 corresponds to "worst photophobia".

Time frame:
28 days
Reported as:
Mean · mm
Change From Baseline in Photophobia Post Dose Instillation on Day 28
mmVoclosporin Ophthalmic Solution (VOS)Comparator
Change From Baseline in Photophobia Post Dose Instillation on Day 28-23.1 ± 26.35-26.2 ± 25.91
Statistical analysis
  • Voclosporin Ophthalmic Solution (VOS) vs Comparator · ANCOVA · p = 0.5356 · Mean difference (final values): 2.8 · 95% CI -6.1 to 11.6
SecondaryChange From Baseline in Eye Pain Post Dose Instillation on Day 28

Eye pain was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no eye pain" and 100 corresponds to "worst eye pain".

Time frame:
28 days
Reported as:
Mean · mm
Change From Baseline in Eye Pain Post Dose Instillation on Day 28
mmVoclosporin Ophthalmic Solution (VOS)Comparator
Change From Baseline in Eye Pain Post Dose Instillation on Day 28-13.9 ± 31.39-19.9 ± 28.62
Statistical analysis
  • Voclosporin Ophthalmic Solution (VOS) vs Comparator · ANCOVA · p = 0.1787 · Mean difference (final values): 5.7 · 95% CI -2.7 to 14.1
SecondaryChange From Baseline in Eye Dryness Post Dose Instillation on Day 28

Eye dryness was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no eye dryness" and 100 corresponds to "worst eye dryness".

Time frame:
28 days
Reported as:
Mean · mm
Change From Baseline in Eye Dryness Post Dose Instillation on Day 28
mmVoclosporin Ophthalmic Solution (VOS)Comparator
Change From Baseline in Eye Dryness Post Dose Instillation on Day 28-35.0 ± 27.59-34.6 ± 27.73
Statistical analysis
  • Voclosporin Ophthalmic Solution (VOS) vs Comparator · ANCOVA · p = 0.7666 · Mean difference (final values): -1.6 · 95% CI -12.6 to 9.3
SecondaryChange From Baseline in Itching Post Dose Instillation on Day 28

Itching was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no itching" and 100 corresponds to "worst itching".

Time frame:
28 days
Reported as:
Mean · mm
Change From Baseline in Itching Post Dose Instillation on Day 28
mmVoclosporin Ophthalmic Solution (VOS)Comparator
Change From Baseline in Itching Post Dose Instillation on Day 28-26.9 ± 27.41-28.1 ± 30.88
Statistical analysis
  • Voclosporin Ophthalmic Solution (VOS) vs Comparator · ANCOVA · p = 0.8082 · Mean difference (final values): -1.2 · 95% CI -10.7 to 8.4
SecondaryChange From Baseline in the Total of All Individual Symptom Severity Assessment Scores

The Individual Symptom Severity Assessment Visual Analog Scale (VAS) includes Burning/Stinging (scale 0 - 100; 0 = no Burning/Stinging, 100 = worst Burning/Stinging), Foreign Body Sensation (scale 0 - 100; 0 = no Foreign Body Sensation, 100 = worst Foreign Body Sensation), Photophobia (scale 0 - 100; 0 = no Photophobia, 100 = worst Photophobia), Eye Pain (scale 0 - 100; 0 = no Eye Pain, 100 = worst Eye Pain), Eye Dryness (scale 0 - 100; 0 = no Eye Dryness, 100 = worst Eye Dryness), and Itching (scale 0 - 100; 0 = no Itching, 100 = worst Itching). The total sum of all 6 symptoms (Burning/Stinging, Foreign Body Sensation, Photophobia, Eye Pain, Eye Dryness, Itching) were evaluated (scale 0 - 600; 0 = no visual symptoms, 600 = worst visual symptoms).

Time frame:
Day 28
Reported as:
Mean · mm
Change From Baseline in the Total of All Individual Symptom Severity Assessment Scores
mmVoclosporin Ophthalmic Solution (VOS)Comparator
Change From Baseline in the Total of All Individual Symptom Severity Assessment Scores-130.9 ± 144.95-149.6 ± 126.16
Statistical analysis
  • Voclosporin Ophthalmic Solution (VOS) vs Comparator · ANCOVA · p = 0.6362 · Mean difference (final values): 11.6 · 95% CI -37 to 60.3
SecondaryChange From Baseline in Symptom Assessment in Dry Eye Score (SANDE)

The Symptom Assessment in Dry Eye (SANDE) is a subjective rating performed by the subjects for the frequency and severity of their dry eye symptoms. The total length of the line is 100mm. For Frequency of Symptoms 0mm = "rarely" and 100mm = "all the time". For Severity of Symptoms 0mm = "very mild" and 100mm = "very severe". Subjects were asked to subjectively rate the frequency and severity of their symptoms by placing an "X" on the relevant horizontal line. The length of the line between the "rarely" or "very mild" starting point and the first point where the subject's mark crosses each line was measured and recorded in millimeters.

Time frame:
Day 28
Reported as:
Mean · mm
Change From Baseline in Symptom Assessment in Dry Eye Score (SANDE)
mmVoclosporin Ophthalmic Solution (VOS)Comparator
Frequency-28.0 ± 29.37-37.9 ± 27.24
Severity-24.9 ± 34.06-36.1 ± 24.84
Statistical analysis
  • Voclosporin Ophthalmic Solution (VOS) vs Comparator · ANCOVA · p = 0.0961 (Frequency) · Mean difference (final values): 9.6 · 95% CI -1.7 to 20.9
  • Voclosporin Ophthalmic Solution (VOS) vs Comparator · ANCOVA · p = 0.1722 · Mean difference (final values): 7.7 · 95% CI -3.4 to 18.7
SecondaryChange From Baseline in Unanesthetized Schirmer Test Score

The Schirmer Test Score recorded tear production on test strips. The Schirmer tear test was conducted 1 hour following administration of VOS/Comparator and 20 minutes following fluorescein corneal staining. Using a ruler and/or the millimeters recorded on the strips, a point halfway between the two lines was measured and this was recorded as the amount of wetting. Lower scores indicate less tear production and therefore a worse outcome. Normal tear production is ≥10mm of wetting on the test strip, and severe dry eye is \<5mm of wetting on the test strip.

Time frame:
28 days
Reported as:
Mean · mm
Change From Baseline in Unanesthetized Schirmer Test Score
mmVoclosporin Ophthalmic Solution (VOS)Comparator
Left Eye8.5 ± 10.523.0 ± 9.03
Right Eye8.2 ± 10.643.3 ± 8.39
Statistical analysis
  • Voclosporin Ophthalmic Solution (VOS) vs Comparator · ANCOVA · p = 0.0051 (Left Eye) · Mean difference (final values): 5.2 · 95% CI 1.6 to 8.9
  • Voclosporin Ophthalmic Solution (VOS) vs Comparator · ANCOVA · p = 0.0104 (Right Eye) · Mean difference (final values): 4.8 · 95% CI 1.1 to 8.4
SecondaryChange From Baseline in Fluorescein Corneal Staining (FCS) Score

The FCS score was summarized for each eye separately. Each of the 5 sections of cornea (superior, inferior, nasal, temporal, central) were graded using the National Eye Institute (NEI) scale; 0, 1 (mild), 2 (moderate), or 3 (severe). The total score was obtained by summing each of the 5 sections of the cornea from 0 - 15. Lower scores indicate less staining and therefore a better outcome.

Time frame:
28 days
Reported as:
Mean · mm
Change From Baseline in Fluorescein Corneal Staining (FCS) Score
mmVoclosporin Ophthalmic Solution (VOS)Comparator
Left Eye-2.2 ± 2.90-0.2 ± 3.05
Right Eye-2.2 ± 3.15-0.7 ± 2.79
Statistical analysis
  • Voclosporin Ophthalmic Solution (VOS) vs Comparator · ANCOVA · p = 0.0003 (Left Eye) · Mean difference (final values): -2.1 · 95% CI -3.2 to -1.0Add in RE LE info
  • Voclosporin Ophthalmic Solution (VOS) vs Comparator · ANCOVA · p = 0.0038 (Right Eye) · Mean difference (final values): -1.6 · 95% CI -2.6 to -0.5

Adverse events

Collected over 28 days +/- 3 days (follow-up period). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Voclosporin Ophthalmic Solution (VOS)0/51 (0%)0/51 (0%)10/51 (19.6%)
Comparator0/49 (0%)0/49 (0%)6/49 (12.2%)
Most frequent other events
Most frequent other events
EventVoclosporin Ophthalmic Solution (VOS)Comparator
Ocular DiscomfortEye disorders7/515/49
Instillation site painGeneral disorders3/511/49
Lacrimation increasedEye disorders0/512/49

Baseline characteristics

Age, Continuous
Age, Continuous(years)Voclosporin Ophthalmic Solution (VOS)ComparatorTotal
Mean57.5 ± 14.5160.2 ± 15.0858.9 ± 14.78
Sex: Female, Male
Sex: Female, Male(Participants)Voclosporin Ophthalmic Solution (VOS)ComparatorTotal
Female423880
Male91120
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Voclosporin Ophthalmic Solution (VOS)ComparatorTotal
Hispanic or Latino131023
Not Hispanic or Latino383977
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Voclosporin Ophthalmic Solution (VOS)ComparatorTotal
American Indian or Alaska Native000
Asian235
Native Hawaiian or Other Pacific Islander000
Black or African American13821
White353671
More than one race011
Unknown or Not Reported112
Duration of Dry Eye Disease
Duration of Dry Eye Disease(years)Voclosporin Ophthalmic Solution (VOS)ComparatorTotal
Median2.85 (1.62 to 6.13)2.67 (1.25 to 6.27)2.85 (1.45 to 6.14)
08

Study locations

7 sites
  • Aurinia Investigative Center
    Garden Grove, California 92843, United States
  • Aurinia Investigative Center
    Mission Hills, California 91345, United States
  • Aurinia Investigative Center
    Rancho Cordova, California 95670, United States
  • Aurinia Investigative Center
    Kansas City, Missouri 64111, United States
  • Aurinia Investigative Center
    Washington, Missouri 63090, United States
  • Aurinia Investigative Center
    High Point, North Carolina 27262, United States
  • Aurinia Investigative Center
    Memphis, Tennessee 38119, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Nov 2018, 2 months.

Results were first posted in Jul 2021, 2 years 7 months after primary completion. A results delay was requested in Jan 2019.

Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 2 months is below that.

Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2018
First posted
Jul 24, 2018
StartActual
Aug 13, 2018
Primary completionActual
Nov 9, 2018
CompletionActual
Dec 13, 2018
Results delay requested
Jan 22, 2019
Results first posted
Jul 8, 2021
Last update
Jul 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03597139
Lead sponsor
Aurinia Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Jul 24, 2018
Start date
Aug 13, 2018
Primary completion
Nov 9, 2018
Completion
Dec 13, 2018
Results posted
Jul 8, 2021
Last update
Jul 8, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Voclosporin

Start the discussion